These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 27183782)
81. Design and synthesis of novel pyrimido[5,4-d]pyrimidine derivatives as GPR119 agonist for treatment of type 2 diabetes. Fang Y; Xu J; Li Z; Yang Z; Xiong L; Jin Y; Wang Q; Xie S; Zhu W; Chang S Bioorg Med Chem; 2018 Aug; 26(14):4080-4087. PubMed ID: 30100020 [TBL] [Abstract][Full Text] [Related]
82. G-protein-coupled receptors (GPCRs) in the treatment of diabetes: Current view and future perspectives. Sebastiani G; Ceccarelli E; Castagna MG; Dotta F Best Pract Res Clin Endocrinol Metab; 2018 Apr; 32(2):201-213. PubMed ID: 29678286 [TBL] [Abstract][Full Text] [Related]
83. Design, synthesis and biological evaluation of novel 7-azaspiro[3.5]nonane derivatives as GPR119 agonists. Matsuda D; Kawamura M; Kobashi Y; Shiozawa F; Suga Y; Fusegi K; Nishimoto S; Kimura K; Miyoshi M; Takayama N; Kakinuma H; Ohtake N Bioorg Med Chem; 2018 May; 26(8):1832-1847. PubMed ID: 29486951 [TBL] [Abstract][Full Text] [Related]
84. Recent developments in the discovery of FFA1 receptor agonists as novel oral treatment for type 2 diabetes mellitus. Defossa E; Wagner M Bioorg Med Chem Lett; 2014 Jul; 24(14):2991-3000. PubMed ID: 24881568 [TBL] [Abstract][Full Text] [Related]
85. Structural basis for constitutive activity and agonist-induced activation of the enteroendocrine fat sensor GPR119. Engelstoft MS; Norn C; Hauge M; Holliday ND; Elster L; Lehmann J; Jones RM; Frimurer TM; Schwartz TW Br J Pharmacol; 2014 Dec; 171(24):5774-89. PubMed ID: 25117266 [TBL] [Abstract][Full Text] [Related]
86. Molecular matchmaking between the popular weight-loss herb Hoodia gordonii and GPR119, a potential drug target for metabolic disorder. Zhang S; Ma Y; Li J; Ma J; Yu B; Xie X Proc Natl Acad Sci U S A; 2014 Oct; 111(40):14571-6. PubMed ID: 25246581 [TBL] [Abstract][Full Text] [Related]
87. Parameterization of the GPR119 Receptor Agonist AR231453. Hamilton J; Kotsikorou E J Comput Chem; 2018 Jan; 39(1):35-41. PubMed ID: 29023843 [TBL] [Abstract][Full Text] [Related]
88. Design, synthesis, and biological evaluation of aryl N-methoxyamide derivatives as GPR119 agonists. Jang YK; Lee KM; Jung KY; Kang SK; Pagire SH; Lee JM; Pagire HS; Kim KR; Bae MA; Lee H; Rhee SD; Ahn JH Bioorg Med Chem Lett; 2017 Aug; 27(16):3909-3914. PubMed ID: 28666737 [TBL] [Abstract][Full Text] [Related]
89. Synthesis and biological evaluation of 1, 2, 4-oxadiazole derivatives as novel GPR119 agonists. Fu S; Xiang W; Chen J; Ma L; Chen L Chem Biol Drug Des; 2017 May; 89(5):815-819. PubMed ID: 27779815 [TBL] [Abstract][Full Text] [Related]
90. [Membrane fatty acid receptors in the β-cell: novel therapeutic targets for type 2 diabetes]. Mancini AD; Poitout V Med Sci (Paris); 2013; 29(8-9):715-21. PubMed ID: 24005625 [TBL] [Abstract][Full Text] [Related]
91. Biological characteristics and agonists of GPR120 (FFAR4) receptor: the present status of research. Li A; Li Y; Du L Future Med Chem; 2015; 7(11):1457-68. PubMed ID: 26230883 [TBL] [Abstract][Full Text] [Related]
92. Discovery of a novel series of indoline carbamate and indolinylpyrimidine derivatives as potent GPR119 agonists. Sato K; Sugimoto H; Rikimaru K; Imoto H; Kamaura M; Negoro N; Tsujihata Y; Miyashita H; Odani T; Murata T Bioorg Med Chem; 2014 Mar; 22(5):1649-66. PubMed ID: 24508142 [TBL] [Abstract][Full Text] [Related]
93. Structural identification of lysophosphatidylcholines as activating ligands for orphan receptor GPR119. Xu P; Huang S; Guo S; Yun Y; Cheng X; He X; Cai P; Lan Y; Zhou H; Jiang H; Jiang Y; Xie X; Xu HE Nat Struct Mol Biol; 2022 Sep; 29(9):863-870. PubMed ID: 35970999 [TBL] [Abstract][Full Text] [Related]
94. Synthesis and biological evaluation of pyrimidine derivatives with diverse azabicyclic ether/amine as novel GPR119 agonist. Yang Z; Fang Y; Park H Bioorg Med Chem Lett; 2017 Jun; 27(11):2515-2519. PubMed ID: 28408218 [TBL] [Abstract][Full Text] [Related]
95. G Protein-Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus. Riddy DM; Delerive P; Summers RJ; Sexton PM; Langmead CJ Pharmacol Rev; 2018 Jan; 70(1):39-67. PubMed ID: 29233848 [TBL] [Abstract][Full Text] [Related]
96. Discovery of phenyl acetamides as potent and selective GPR119 agonists. Zhu C; Wang L; Zhu Y; Guo ZZ; Liu P; Hu Z; Szewczyk JW; Kang L; Chicchi G; Ehrhardt A; Woods A; Seo T; Woods M; van Heek M; Dingley KH; Pang J; Salituro GM; Powell J; Terebetski JL; Hornak V; Campeau LC; Orr RK; Ujjainwalla F; Miller M; Stamford A; Wood HB; Kowalski T; Nargund RP; Edmondson SD Bioorg Med Chem Lett; 2017 Mar; 27(5):1124-1128. PubMed ID: 28185720 [TBL] [Abstract][Full Text] [Related]
97. Novel FFA1 (GPR40) agonists containing spirocyclic periphery: polar azine periphery as a driver of potency. Krasavin M; Lukin A; Bagnyukova D; Zhurilo N; Zahanich I; Zozulya S J Enzyme Inhib Med Chem; 2017 Dec; 32(1):29-36. PubMed ID: 27781494 [TBL] [Abstract][Full Text] [Related]
98. Quercetin/oleic acid-based G-protein-coupled receptor 40 ligands as new insulin secretion modulators. Badolato M; Carullo G; Perri M; Cione E; Manetti F; Di Gioia ML; Brizzi A; Caroleo MC; Aiello F Future Med Chem; 2017 Oct; 9(16):1873-1885. PubMed ID: 29064290 [TBL] [Abstract][Full Text] [Related]
99. GPR40 carboxylic acid receptor family and diabetes: a new drug target. Telvekar VN; Kundaikar HS Curr Drug Targets; 2008 Oct; 9(10):899-910. PubMed ID: 18855625 [TBL] [Abstract][Full Text] [Related]
100. Evaluation of anti-diabetic effect and gall bladder function with 2-thio-5-thiomethyl substituted imidazoles as TGR5 receptor agonists. Zhang X; Sui Z; Kauffman J; Hou C; Chen C; Du F; Kirchner T; Liang Y; Johnson D; Murray WV; Demarest K Bioorg Med Chem Lett; 2017 Apr; 27(8):1760-1764. PubMed ID: 28285911 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]